HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
Active, not recruiting
Alnylam Pharmaceuticals
Phase 3
2019-02-14
The purpose of this study is to evaluate the efficacy and safety of vutrisiran (ALN-TTRSC02)
in patients with hereditary transthyretin amyloidosis (hATTR amyloidosis). Participants will
receive vutrisiran or the reference comparator patisiran during the Treatment Period. The
Treatment Period is followed by a Treatment Extension Period during which all participants in
the patisiran group will switch to vutrisiran. This study will use the placebo arm of the
APOLLO study (NCT01960348) as an external comparator for the primary and most other efficacy
endpoints.
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Active, not recruiting
Alnylam Pharmaceuticals
Phase 3
2019-11-26
This study will evaluate the efficacy and safety of vutrisiran 25 mg administered
subcutaneously (SC) once every 3 months (q3M) compared to placebo in patients with ATTR
amyloidosis with cardiomyopathy.
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
ENROLLING_BY_INVITATION
Alnylam Pharmaceuticals
PHASE3
2024-12-03
The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from patisiran.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
